Cargando…

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Bamlanivimab-etesevimab and casirivimab-imdevimab are authorized by the US Food and Drug Administration for emergency treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk persons. There has been no study comparing their clinical efficacy. In this retrospective study of 681...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Horo, John, Challener, Douglas W., Anderson, Ryan J., Arndt, Richard F., Ausman, Sara E., Hall, Scott T., Heyliger, Alexander, Kennedy, Brian D., Sweeten, Perry W., Ganesh, Ravindra, Razonable, Raymund R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mayo Foundation for Medical Education and Research 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864104/ https://www.ncbi.nlm.nih.gov/pubmed/35512884 http://dx.doi.org/10.1016/j.mayocp.2022.02.009

Ejemplares similares

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
por: Mazzotta, Valentina, et al.
Publicado: (2022)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

550. Bamlanivimab and Casirivimab/Imdevimab Treatment Outcomes: Results from a Large Healthcare System’s Structured Implementation Experience
por: Polk, Christopher, et al.
Publicado: (2021)

Bamlanivimab/casirivimab/imdevimab: Burning, eye pain and lack of efficacy following off-label use: 8 case reports
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
por: Heller, Martin, et al.
Publicado: (2023)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Efficacy of Casirivimab/Imdevimab in Kidney Transplant Recipients Admitted with Mild-to-Moderate COVID-19: A Case Series
por: Rajmane, Siddhavinayak Suryakant, et al.
Publicado: (2023)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
por: Liu, Esther C., et al.
Publicado: (2021)

Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
Publicado: (2022)

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
por: Markovitz, Netana H., et al.
Publicado: (2022)

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021)

Dégradation respiratoire post Casirivimab/Imdevimab : fréquence et facteurs de risque
por: Gerber, V., et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
por: Abou-Jaoude, E., et al.
Publicado: (2022)

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
por: Suzuki, Yasuhito, et al.
Publicado: (2022)

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
por: Phan, Alexander T, et al.
Publicado: (2021)

1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
por: Simpson, Michelle, et al.
Publicado: (2022)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
por: Laurini, Erik, et al.
Publicado: (2021)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
por: Pillai, Rajapillai L. I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_npgcath0rdeqf2t4tsj8esppa3